Tracker Update: Five Situations Resolved, One Walked Away
A pass over every open row in the Deal Tracker, catching up the deals that have closed, listed or died since they were first logged.
The tracker had been recording deals at the moment we wrote about them and then leaving them there. That is fine for a rumour, less fine for a deal that has since completed. Five situations have been brought up to date, and the duplicate rows created as long-running stories developed have been merged into one row each.
SpaceX is public. The row still read “IPO Filing” from the S-1 in May. SpaceX priced at $135 and began trading on 12 June under SPCX, opening at $150 and closing its first day at $160.95. It now sits in the tracker as listed.
SpaceX/Cursor has completed. The $60bn all-stock purchase of Anysphere closed on 14 August, two months after it was agreed. Logged as closed.
Castlelake is out of easyJet. After five proposals, Castlelake confirmed on 6 August that it would not bid, hours before Apollo agreed terms at 715p a share. The Castlelake row is now marked terminated rather than deleted, because a failed approach is still information: it tells you what the asset was worth to someone who walked.
Frasers got 47.89% of Hugo Boss, not control. The offer went unconditional after EU merger clearance, but only about 17.6% of shareholders tendered. Frasers says it still wants a majority and will not say when or at what price.
Prologis/Segro is agreed, not done. Worth stating plainly because the row had drifted through five entries at five different valuations as the bidding moved. One row now, at the agreed $18.8bn, closing expected in the first half of 2027.
Everything else in the tracker stays where it was. Of 77 open situations, 51 are agreed and awaiting completion, 15 remain at the rumour stage, nine have closed and one has died. That last number will grow, and it is the one worth watching: the share of announced deals that never complete is the cheapest available read on how hard the regulatory and financing environment has become.